- Home
- SAVA vs NTHI Comparison
SAVA vs NTHI Comparison
Compare SAVA & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- NTHI
- Stock Information
- Founded
- SAVA 1998
- NTHI 2008
- Country
- SAVA United States
- NTHI United States
- Employees
- SAVA N/A
- NTHI N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- SAVA Health Care
- NTHI Health Care
- Exchange
- SAVA Nasdaq
- NTHI Nasdaq
- Market Cap
- SAVA 102.4M
- NTHI 110.9M
- IPO Year
- SAVA N/A
- NTHI N/A
- Fundamental
- Price
- SAVA $2.34
- NTHI $5.12
- Analyst Decision
- SAVA Hold
- NTHI
- Analyst Count
- SAVA 1
- NTHI 0
- Target Price
- SAVA $2.00
- NTHI N/A
- AVG Volume (30 Days)
- SAVA 867.7K
- NTHI 320.0K
- Earning Date
- SAVA 08-14-2025
- NTHI 01-01-0001
- Dividend Yield
- SAVA N/A
- NTHI N/A
- EPS Growth
- SAVA N/A
- NTHI N/A
- EPS
- SAVA N/A
- NTHI N/A
- Revenue
- SAVA N/A
- NTHI $79,990.00
- Revenue This Year
- SAVA N/A
- NTHI N/A
- Revenue Next Year
- SAVA N/A
- NTHI N/A
- P/E Ratio
- SAVA N/A
- NTHI N/A
- Revenue Growth
- SAVA N/A
- NTHI 13.52
- 52 Week Low
- SAVA $1.15
- NTHI $3.20
- 52 Week High
- SAVA $33.98
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- SAVA 54.06
- NTHI N/A
- Support Level
- SAVA $2.20
- NTHI N/A
- Resistance Level
- SAVA $2.43
- NTHI N/A
- Average True Range (ATR)
- SAVA 0.17
- NTHI 0.00
- MACD
- SAVA -0.00
- NTHI 0.00
- Stochastic Oscillator
- SAVA 60.42
- NTHI 0.00
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").